Another pivotal recent RCT is the OPTIMA‐AF, a multicenter, open‐label RCT in Japan to evaluate the comparable efficacy and safety of short‐term (1‐month DOAC with a P2Y12 inhibitor) and long‐term (12‐month DOAC with a P2Y12 inhibitor) dual therapy followed by DOAC monotherapy in 1079 patients with AF undergoing PCI for chronic CAD or unstable angina [28]. Here, P2RY12 is linked to angina unstable.